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Background: In Thailand and Southeast Asia, Brugada syndrome (BS) is a common inheritable cause of
sudden cardiac arrest (SCA) due to polymorphic ventricular tachycardia (VT) and ventricular ﬁbrillation
(VF). Currently, an implantable cardioverter deﬁbrillator (ICD) is the recommended therapy for high-risk
patients. This study aimed to report the outcomes of symptomatic BS patients with implanted ICD in an
area in which BS is endemic.
Methods and results: We enrolled symptomatic BS patients who underwent ICD implantation between
2007 and 2010. In total, 62 patients met the study inclusion criteria. Among these patients, ICD was
indicated for survivors of SCA (50 patients, 80%) and syncope patients (12 patients, 20%). During the
mean follow-up period of 17 months, no patient died, and 20 patients (32%) received appropriate shock
therapy. Inappropriate shock occurred in 6 patients (9.5%). The reasons for inappropriate shock were ICD
lead fracture (3%) and supraventricular arrhythmia (6.5%). An infected ICD was found in 1 patient (1.5%).
Conclusions: The recurrent VT/VF rate in symptomatic BS patients was 32%. All events were successfully
treated with ICDs, and there was no mortality in our setting.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Brugada syndrome (BS) is characterized by ST segment eleva-
tion (coved type) in the right precordial electrocardiographic
(ECG) leads and sudden cardiac arrest (SCA) or death in patients
with normal cardiac structure. The syndrome typically manifests
during adulthood, with a mean onset age of 41 years [1,2]. The
causes of SCA in BS are polymorphic ventricular tachycardia (VT)
and ventricular ﬁbrillation (VF) [1,2].
In Thailand and Southeast Asia, the incidence of Brugada ECG
type 1 in patients with previous cardiac arrest is higher than that in
the general population in Europe and the United States [3,4]. BS
accounts for 47.2% of all sudden deaths in Northeastern Thailand and
only 4−12% in the rest of the world [3,4]. SCA from VT and VF in BS
patients occurs mainly at rest, predominantly during sleep [5]. Thet Rhythm Society. Published by Els
, MD, PhD, Department of
, 123 Mitraparp Road, Khon
uth).typical ECG pattern changes over time and is mediated by post-
exercise or pharmacologic interventions that interact with the
autonomic nervous system (ANS) [6]. ST segment elevation in leads
V1–V3 could be augmented by administration of sodium channel
blockers and high intercostal ECG lead placement in patients with
suspected BS who are at risk for VT/VF [7].
The implantable cardioverter deﬁbrillator (ICD) is more effective
than antiarrhythmic drugs for symptomatic BS patients, including
those with aborted SCA and syncope [8,9]. The average mortality
rate of BS from recurrent VT/VF may be high as 25% [10]; therefore,
BS is considered the main public health problem in Northeastern
Thailand and the Southeast Asian countries. By 2015, the Associa-
tion of Southeast Asian Nations (ASEAN) Economic Community
(AEC) project will be implemented by all governments in Southeast
Asia. This project will allow Southeast Asians to work freely in any
country in the region. Increased travel, particularly among workers
in ASEAN countries, will occur. SCA was reported in a group of Thai
workers in Singapore in the 1990s [11]. Therefore, healthcare
personnel in the ASEAN community and Asia should be aware of
this fatal condition in the years after 2015. More scientiﬁc reports ofevier B.V. All rights reserved.
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the clinical outcomes of symptomatic BS patients treated with ICDs.2. Material and methods
2.1. Study population
All patients diagnosed with BS who underwent ICD implanta-
tion at Queen Sirikit Heart Center of The Northeast (QSHC) and
Srinagarind Hospital, Khon Kaen University, Thailand between
2007 and 2010 were included.
2.2. Diagnosis and clinical data
BS is clinically diagnosed in patients presenting with SCA or
syncope on the basis of one of the following criteria: documented VT
or VF, family history of sudden cardiac death at o45 years of age,
similar type of Brugada ECG among family members, unexplained
syncope, history of nocturnal agonal respiration with spontaneous
type 1 Brugada ECG, or type 1 Brugada ECG after provocation using
high intercostal ECG lead detection or after sodium channel blocker
administration. A type 1 ECG was deﬁned as a prominent coved ST
segment elevation 42 mm followed by a negative T wave [10,12].
The following clinical data were collected: age at diagnosis, sex,
family history of SCA, type of Brugada ECG at diagnosis, results of
pharmacological testing or high intercostal lead detection for
unmasking the coved type ECG pattern, presenting symptoms
(survivor of SCA or syncope), and indication for ICD implantation.
In addition, the following criteria were considered: device effec-
tiveness assessed by the numbers of patients who received
appropriate shock after ICD implantation (only the ﬁrst appro-
priate shock was considered for analysis) and complications,
including inappropriate shock and uneventful events after ICD
implantation. All patients attended follow-up visits every 3−6
months for clinical review and device evaluation.
2.3. Statistical analysis
Clinical characteristics of the BS patients were categorized by
presenting symptoms (SCA or unexplained syncope). Data are
expressed as mean (standard deviation [SD]) or percentage. The
unpaired t-test was used for comparisons of group mean values
expressed as continuous variables, while the chi-square or Fisher's
exact test was used to test differences in proportion. A p value
o0.05 was considered statistically signiﬁcant.3. Results
3.1. Clinical characteristics
The demographic and clinical characteristics of the study
population are summarized in Table 1. A total of 62 patients wereTable 1
Clinical characteristics of 62 Brugada syndrome patients grouped according to presenti
Characteristic Sudden ca
Mean age7standard deviation (years) 46712
Men (%) 50 (100%)
Family history of sudden death (%) 22 (44%)
Spontaneous type 1 ECG 38 (70%)
Type 1 ECG after high intercostal lead 8 (16%)
Type 1 ECG after sodium channel blocker administration 4 (8%)
Residency region in Thailand –Northeastern 48 (96%)
ECG: electrocardiogram.studied. Of these patients, 50 (80.6%) presented with SCA and 12
(19.4%) presented with syncope. Almost all patients were men
(61 patients, 98.4%) and were born and living in Northeastern
Thailand (60 patients, 96.8%). The mean (SD) age at diagnosis was
45 (9) years. A family history of SCA was noted in 26 patients
(42%). A spontaneous coved-type Brugada ECG pattern was found
in most patients (47 patients, 75.8%). The average follow-up period
for all patients was 17 months.
3.2. Clinical comparison according to presenting symptom
There was no signiﬁcant difference between BS patients pre-
senting with SCA or syncope in terms of age, sex, family history of
SCA, or ECG type (Table 1).
3.3. Clinical outcomes and complications of ICD
The clinical outcomes and complications of the patients with
implanted ICDs are shown in Table 2. A single-chamber ICD was
implanted in all patients. Twenty patients (32.3%) had recurrent VT/
VF and were successfully treated with ICD or appropriate shock. Of
these patients, 16 (80.0%) were in the SCA group. Eight patients (40%)
received ICD shock when they were awake, and the shock occurred
during the night for the other 12 patients (60%). Inappropriate shock
by ICD occurred in 6 patients (9.7%), 3 in each group. Patients
received amiodarone if there was evidence of recurrent VT/VF due to
appropriate shocks. Reasons for inappropriate shock were ICD lead
fracture (2 patients, 3%) and supraventricular arrhythmia (4 patients,
6.5%). Supraventricular arrhythmias consisted of sinus tachycardia (2
patients), supraventricular tachycardia (1 patient), and atrial ﬁbrilla-
tion (1 patient). One patient (1.5%) in the syncope group had an
infected ICD, which was removed and reimplanted after successful
treatment of the infection.4. Discussion
This study showed the rate of recurrent of VT/VF in sympto-
matic Thai BS patients who received ICD implantation as a
secondary prevention. After approximately 1.5 years of follow-
up, the recurrence of VT/VF in symptomatic BS patients in our
series was 32%. All events were successfully treated by ICDs. The
event rate in Thai patients was comparable with from the rate
in other countries. After 3 years of follow-up of symptomatic
Japanese BS patients, the rate of recurrent cardiac events after ICD
implantation or secondary prevention was 25.7% [13]. Similarly,
the VT/VF rate in European BS patients treated with ICD was
somewhat higher, at 34% [13]. A report from France showed that
most BS patients received ICD shock at random times, whereas in
the present study, most patients (60%) experienced cardiac events
during the night, similar to the ﬁndings of a previous report [3,9].
Thus, symptomatic BS patients in our region had cardiac events
more frequently while they were sleeping.ng symptoms.
rdiac arrest (n¼50) Syncope (n¼12) p value
4479 0.058
11 (92%) 0.194
4 (33.3%) 0.531
9 (75%) 0.942
2 (16.7%) 0.955
1 (4.3%) 0.970
12 (100%) 1.000
Table 2
Outcome of 62 Brugada syndrome patients grouped according to presenting symptoms.
Characteristic Sudden cardiac arrest (n¼50) Syncope (n¼12) p value
Mean follow-up time7standard deviation (months) 1674 1876 0.067
Patients with appropriate shock, n (%) 16 (32%) 4 (33.3%) 0.929
Patients with inappropriate shock, n (%) 3 (6.0%) 3 (25.0%) 0.081
Infected ICD, n (%) 0 (0%) 1 (8.3%) 0.193
ICD: implantable cardioverter deﬁbrillator.
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symptomatic BS, some complications may occur after ICD implan-
tation. In our study, inappropriate ICD shock occurred substan-
tially less frequently compared to appropriate shock (9.7% vs.
32.3%). The inappropriate shock rate was lower than that of a
previous report (20%) [14]. Depression or fear of shock therapy
may occur in BS patients who receive inappropriate shocks [15]. In
our study, the appropriate ICD shock rate was higher than that in
the report by Sacher et al. (32.3% vs. 8%) [14]. This ﬁnding may be
explained by differences in the study populations. In the present
study, 50 of 62 patients (80.64%) were symptomatic and had SCA.
However, SCA patients accounted for only 8% of all patients in the
previous study [14]. To avoid inappropriate shock, adjustment of
the ICD to only 1 VF zone with a detection rate above 180
−200 bpm in young, active patients is recommended [16]. Another
serious complication of infected ICD occurred in only 1 patient
(1.6%). Because of the high rate of recurrent VT/VF and low rate of
ICD complications, ICD treatment is recommended for all sympto-
matic BS patients [8–10].
Several clinical parameters have been demonstrated to predict
a worse outcome in BS patients, including severe symptoms at
diagnosis (SCA), spontaneous type 1 Brugada ECG at diagnosis,
male sex, and family history of SCA [10]. The results of this study
conﬁrmed that symptomatic BS patients in our setting, particularly
those presenting with SCA, should receive ICD therapy because of
a high probability of recurrent VT/VF events. Subsequent device
programming and regular follow-up are required to minimize the
occurrence of inappropriate shock.5. Conclusions
The recurrent VT/VF rate in symptomatic Thai BS patients was
high, and these events were successfully treated with ICDs in our
setting.Conﬂicts of interests
none declared.References
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